NDAORALTABLET
Approved
Apr 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCODAN-DEMI is a fixed-dose combination tablet containing aspirin and two forms of oxycodone (hydrochloride and terephthalate), an opioid analgesic. This product is indicated for moderate pain relief and combines anti-inflammatory (aspirin) with opioid analgesia. It represents a legacy combination approach to pain management that predates modern multimodal analgesia protocols.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a mature brand with likely declining team size and transition-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PERCODAN-DEMI offers limited career growth given the product's approaching LOE and absence of linked job openings (0 roles). Career value lies in legacy brand management experience, managed care negotiation, and post-LOE transition strategies rather than innovation or market expansion.
Brand Manager (legacy/mature)Field Sales Representative
Worked on PERCODAN-DEMI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.